Literature DB >> 7883423

Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival.

M L Carcangiu1, J T Chambers.   

Abstract

Clear cell carcinoma (CCC) and uterine papillary serous carcinoma (UPSC) are aggressive variants of endometrial carcinoma that may coexist or share some clinicopathologic features suggesting a similar biologic spectrum and the need for a common therapeutic approach. Twenty-nine cases of pathologic FIGO stage I and II CCC and 47 cases of FIGO stage I and II UPSC seen and treated at Yale-New Haven Hospital were reviewed, and the survival rates with regard to various pathological parameters were compared. Both groups of patients had similar clinical profiles with respect to presentation, age, weight, and medical problems. The 5-year survival for pathologic stage I patients with CCC was 72% and for those with UPSC 44%. The 5-year survival for pathologic stage II patients with CCC was 59% and for those with UPSC 32%. Analysis of survival showed that the depth of myometrial invasion, the presence of vascular space invasion, and the admixture of endometrioid features did not influence survival in either group of patients. In CCC, survival was also not influenced by the predominant histologic pattern, i.e., papillary versus nonpapillary. The results of this study suggest that early stage CCC and UPSC have similar clinicopathologic profiles, suggesting the need for aggressive approaches including a staging laparotomy and possibly similar therapy. However, the stage I CCC patients had a significantly better survival than the stage I UPSC patients.

Entities:  

Mesh:

Year:  1995        PMID: 7883423     DOI: 10.1097/00004347-199501000-00006

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  21 in total

1.  A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?

Authors:  June Y Hou; Thomas C McAndrew; Gary L Goldberg; Kathleen Whitney; Shohreh Shahabi
Journal:  Reprod Sci       Date:  2013-09-10       Impact factor: 3.060

2.  Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.

Authors:  Shannon D Armbruster; Rebecca Previs; Pamela T Soliman; Shannon N Westin; Bryan Fellman; Anuja Jhingran; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2019-06-18       Impact factor: 5.482

Review 3.  Practical issues in the diagnosis of serous carcinoma of the endometrium.

Authors:  Sonia Gatius; Xavier Matias-Guiu
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

4.  Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).

Authors:  Karim El-Sahwi; Stefania Bellone; Emiliano Cocco; Francesca Casagrande; Marta Bellone; Maysa Abu-Khalaf; Natalia Buza; Fattaneh A Tavassoli; Pei Hui; Dominik Rüttinger; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  Mol Cancer Ther       Date:  2010-01-06       Impact factor: 6.261

5.  Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases.

Authors:  Oluwole Fadare; Wenxin Zheng; Marta A Crispens; Howard W Iii Jones; Dineo Khabele; Katja Gwin; Sharon X Liang; Khaled Mohammed; Mohamed M Desouki; Vinita Parkash; Jonathan L Hecht
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

6.  Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma.

Authors:  E Sivridis; A Giatromanolaki
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

7.  The effect of cell type on surgico-pathologic risk factors in endometrial cancer.

Authors:  Ahmet Taner Turan; Betül Dündar; Burcu Gündoğdu; Abdullah Boztosun; Nejat Ozgül; Nurettin Boran; Gökhan Tulunay; Ahmet Ozfuttu; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

8.  Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.

Authors:  Bojana Djordjevic; Bryan T Hennessy; Jie Li; Bedia A Barkoh; Rajyalakshmi Luthra; Gordon B Mills; Russell R Broaddus
Journal:  Mod Pathol       Date:  2012-02-03       Impact factor: 7.842

9.  Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer.

Authors:  E Cocco; S Bellone; K El-Sahwi; M Cargnelutti; F Casagrande; N Buza; F A Tavassoli; E R Siegel; I Visintin; E Ratner; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

10.  Induction of tumour-specific CD8(+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer.

Authors:  A D Santin; S Bellone; A Ravaggi; J J Roman; S Pecorelli; G P Parham; M J Cannon
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.